Spondyloarthritis & psoriatic arthritis

Transcriptomic profiling of secukinumab-treated psoriatic arthritis reveals potential novel response-associated pathways

Rheumatology (Oxford)Published Mechanistic study

Authors' conclusion

We identified two genes as pre-treatment predictive biomarkers of secukinumab response that persisted over time. Integration with WGCNA revealed five additional candidate genes. These genes are implicated in metabolic pathways, which may modulate the secukinumab response.

Study context

Population
Patients with PsA commencing secukinumab in OUtcomes of Treatment in Psoriatic Arthritis Study Syndicate (OUTPASS), a prospective observational cohort of patients with PsA initiating advanced therapeuticssecukinumab-treated
Participants
13 patients
Comparison
Responders vs non-responders to secukinumab
Outcome
Transcriptomic predictive biomarkers of response (differentially expressed genes (DEGs): adjusted P < 0.05, |log2 fold change| ≥ 1); response by DAS28 criteria and Psoriatic Arthritis Response Criteria
Follow-up
3 months
Methodological detailstranscriptomic (whole-blood RNA sequencing), longitudinal, extreme phenotype response sampling, nested in prospective observational cohort (OUTPASS), Differential gene expression analysis, Ingenuity Pathway Analysis (IPA) and WGCNA; immune cell subset proportions estimated by deconvolution
  • Transcriptomic (whole-blood RNA sequencing)
  • Longitudinal
  • Extreme phenotype response sampling
  • Nested in prospective observational cohort (OUTPASS)
  • Differential gene expression analysis, IPA and WGCNA; immune cell subset proportions estimated by deconvolution

Main finding

As reported in the abstract

Differentially expressed genes in responders · baseline and 3 months
Five overlapping genes (GMPR, CDC34, DMTN, UBXN6, SLC25A39) identified as potential drivers
5

Original publication

Transcriptomic profiling of secukinumab-treated psoriatic arthritis reveals potential novel response-associated pathways. Rheumatology (Oxford). Published 15 April 2026. doi:10.1093/rheumatology/keag193

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.